AstraZeneca (AZN) Updates on OSKIRA-4 Top-Line Results; Did Not Meet Secondary Objective
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
